Mitsubishi Tanabe Pharma closed a stock transfer agreement to acquire the Stelic Institute & Co., that will split prior to the acquisition into the intestinal disease business and other business. Stelic’s intestinal disease pipeline includes STNM01, a siRNA pharmaceutical administered via submucosal injection through an endoscope. The product is under development for ulcerative colitis in Germany and Crohn’s disease in Japan.